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Abstract
Background: In vitro studies have demonstrated that deletions and point mutations introduced into each 21 bp
imperfect repeat of Tax-responsive element (TRE) of the genuine human T-cell leukemia virus type I (HTLV-1) viral
promoter abolishes Tax induction. Given these data, we hypothesized that similar mutations may affect the
proliferation of HTLV-1i
nfected cells and alter the proviral load (PvL). To test this hypothesis, we conducted a cross-sectional genetic
analysis to compare the near-complete LTR nucleotide sequences that cover the TRE1 region in a sample of HTLV-
1 asymptomatic carriers with different PvL burden.
Methods: A total of 94 asymptomatic HTLV-1 carriers with both sequence from the 5’ long terminal repeat (LTR)
and a PvL for Tax DNA measured using a sensitive SYBR Green real-time PCR were studied. The 94 subjects were
divided into three groups based on PvL measurement: 31 low, 29 intermediate, and 34 high. In addition, each
group was compared based on sex, age, and viral genotypes. In another analysis, the median PvLs between
individuals infected with mutant and wild-type viruses were compared.
Results: Using a categorical analysis, a G232A substitution, located in domain A of the TRE-1 motif, was detected
in 38.7% (12/31), 27.5% (8/29), and 61.8% (21/34) of subjects with low, intermediate, or high PvLs, respectively. A
significant difference in the detection of this mutation was found between subjects with a high or low PvL and
between those with a high or intermediate PvL (both p < 0.05), but not between subjects with a low or
intermediate PvL (p > 0.05). This result was confirmed by a non-parametric analysis that showed strong evidence
for higher PvLs among HTLV-1 positive individuals with the G232A mutation than those without this mutation (p <
0.03). No significant difference was found between the groups in relation to age, sex or viral subtypes (p > 0. 05).
Conclusions: The data described here show that changes in domain A of the HTLV-1 TRE-1 motif resulting in the
G232A mutation may increase HTLV-1 replication in a majority of infected subjects.
Background
Human T-cell leukemia virus type I (HTLV-I) is the ret-
rovirus responsible for adult T-cell leukemia (ATL) and
the chronic neurological disorder HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)
[1-4]. The virus has also been implicated in a variety of
inflammatory diseases, such as uveitis [5], pulmonary
alveolitis [6], Hashimoto thyroiditis [7], Sjögren’s syn-
drome [8], and chronic arthropathy [9]. Globally, there
are an estimated 10-20 million individuals are HTLV-I
carriers [10]. The disease burden is unevenly distributed
in endemic areas particularly in southwest Japan, the
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HTLV-1 is classified into seven subtypes [12]: the cos-
mopolitan subtype A, the Central African subtype B, the
Australo-Melanesian subtype C, and subtypes D, E, F
and G. The cosmopolitan subtype A is further divided
into five subgroups: (A) Transcontinental, (B) Japanese,
(C) West African, (D) North African, and (E) Black
[13-16]. Genetic differences between HTLV-1 strains are
not associated with differing clinical outcomes of
HTLV-1 infections [17,18].
Similar to other retroviruses, HTLV-1 carries a diploid
RNA genome comprising 9032 nucleotides that is
reverse-transcribed into double-stranded DNA that inte-
grates into host genome as a provirus. This genome
contains gag, pol and env genes flanked by long terminal
repeat (LTR) sequences at both 5’ and 3’ ends [19]. The
LTR region contains enhancer/promoter genetic ele-
ments, which are critical in viral RNA transcription. A
unique pX region identified between env and the 3’ LTR
encodes two key regulatory proteins Tax and Rex, as
well as the various nonstructural proteins p12I, p27I,
p13II, and p30II [20-22]. The Tax protein is thought to
play a central role in the proliferation of infected cells
and leukemogenesis because of its pleiotropic effects
[23]. Tax modulates the transcription of an array of cel-
lular genes through various cellular transcriptional sig-
naling proteins such as NF-kB, CREB, SRF, AP-1 p53
and basic helix-loop-helix factors [11,24,25]. Tax protein
has also been shown to significantly trans-activate
HTLV RNA transcription via the viral LTR through its
interaction with members of the activating transcription
factor/cAMP-responsive element (CRE) binding protein
bound to the viral promoter, such as ATF-1, CREB,
CREB-2, or cAMP-responsive element modulator
[2,26-28]. The viral promoter is located in the 5’ LTR
and contains three copies of a 21-bp imperfect repeat,
called the Tax-responsive element 1 (TRE-1), that indir-
ectly interacts with the Tax protein [29]. These
sequences are present within the U3 region of the LTR
at positions 251 to 231 (repeat I), 203 to 183 (repeat II),
and 103 to 83 (repeat III) numbered-relative to the tran-
scriptional start site. Each of the repeats is divided into
three domains: A, B, and C. The central domain B of
each repeat contains a conserved TGACG sequence,
which shares homology with CRE, flanked by short GC-
rich sequences [30,31]. Evidence from in vitro studies
has demonstrated that deletions and point mutations
introduced into each 21 bp repeat in the genuine viral
promoter abolishes Tax induction [31,32]. We hypothe-
sized that similar mutations may affect the proliferation
of infected cells and alter the HTLV-1 PvL. Therefore,
we performed a genetic analysis to compare the near
complete LTR nucleotide sequences that cover the TRE
regions in a sample of asymptomatic HTLV-1 carriers
with different levels of PvLs.
Materials and methods
Patients
Peripheral blood samples (5 ml) were collected from 256
HTLV-1 positive carriers identified by the HTLV enzyme
immunoassays Murex HTLV I + II (Abbott/Murex, Wies-
baden, Germany) and Vironostika HTLVI/II (bioMérieux
bv, Boxtel, Netherlands) and confirmed by HTLV BLOT
2.4 (Genelabs Diagnostics, Singapore). Written informed
consent was obtained from each participant. The study
was approved by the local review board.
DNA extraction and HTLV-1 proviral load determination
DNA was extracted from PBMCs using a commercial kit
(Qiagen GmbH, Hilden Germany) following the manu-
facturer’s instructions. The extracted DNA was used as
a template to amplify a 158 bp fragment from the
HTLV-1 Tax region using previously published primers
[33]. The SYBR green real-time PCR assay was carried
out in 25 μl PCR mixture containing 10× Tris (pH 8.3;
Invitrogen, Brazil), 1.5 mM MgCl2, 0.2 μM of each pri-
mer, 0.2 mM of each dNTPs, 18.75 Units/r × n SYBR
Green (Cambrex Bio Science, Rockland, ME) and 1 unit
of platinum Taq polymerase (Invitrogen, Brazil). The
amplification was performed in the Bio-Rad iCycler iQ
system using an initial denaturation step at 95°C for 2
minutes, followed by 50 cycles of 95°C for 30 seconds,
57°C for 30 seconds and 72°C for 30 seconds. The
human housekeeping b globin gene primers GH20 and
PC04 [34] were used as an internal control. A negative,
no-template control (H2O control) was run with every
assay. Standard curves for HTLV-1 Tax were generated
from MT-2 cells of log10 dilutions (from 10
5 to 100
copies). The threshold cycle for each clinical sample was
calculated by defining the point at which the fluores-
cence exceeded a threshold limit. Each sample was
assayed in duplicate, and the mean of the two values
was considered as the copy number of the sample. The
HTLV-1 proviral load was calculated as: the copy num-
ber of HTLV-1 (Tax) per 1,000 cells = (copy number of
HTLV-1 Tax)/(copy number of b globin/2) × 1000 cells.
The method could detect 1 copy per 103 PBMCs cells.
PvLs of <50, between 50 and 100, or > 100 copies/
1000 PBMCs were considered to be a low, medium, or
high PvL, respectively. An HTLV-1 PvL > 100 copies/
1000 PBMCs have previously been shown to be asso-
ciated with an increased risk of HTLV-1 disease [35].
Amplification and sequencing of HTLV-1 LTR proviral
DNA
Sequencing of the near complete LTR region of HTLV-
1 proviral DNA was performed in 94 clinical isolates.
PCR was performed using the primers HFL1 (39) (5’
CCCAAGCTTGACAATGACCATGAGC 3’) and HFL2
(782) (5’CCCGAATTCCAACTGTGTACTAAATTTC
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3’) and in conditions as previously described [36]. Com-
plementary DNA strands from each amplicon were
directly sequenced by cycle sequencing using the same
primers used for PCR, BigDye terminator chemistry and
Taq polymerase on an automated sequencer (ABI 3130,
Applied Biosystems Inc., Foster City, CA), according to
the protocols recommended by the manufacturer. The
complementary sequences for each amplicon were
assembled into a contiguous sequence with a minimum
overlap of 30 bp with a 97-100% minimal mismatch and
edited using the Sequencher program 4.7 (Gene Code
Corp., Ann Arbor, MI). Sequences were then analyzed
using BioEdit v.7.0.4.1 [37] and Geneious Pro v.4.8.4
(Biomatters Ltd, Auckland, New Zealand), and com-
pared with the HTLV-1 ATK prototype (accession num-
ber J02029) [19]. A strain was considered mutant when
it possessed consistent changes in its forward and
reverse sequences compared to the reference wild-type
strain.
HTLV-1 genotyping
The HTLV-1 genotypes were determined by comparing
the sequence of the LTR region to standard sequences
from the GenBank database. HTLV subtyping was per-
formed using the NCBI-Genotyping and REGA-Subtyp-
ing websites.
Statistical analysis
For categorical variables, the Fisher’s exact test or Chi-
square test with Yate’s correction was used when appro-
priate to analyze the association of HTLV-1 PvLs and
the LTR mutational frequency. In another analysis, inde-
pendent of the PvL grouping, the median PvL between
subjects infected with mutant viruses to those infected
with wild-type viruses was compared using the non-
parametric U-Mann-Whitney test. A p value < 0.05 was
considered significant. The data were analyzed with
Stata statistical software (StataCorp, release 5.0, 1997;
Stata, College Station, TX).
Results
Out of the 256 subjects, the quantitative assay classified
71% (n = 182) in the low PvL group (median 6 copies/
1000 PBMCs, range 1 to 47), 11.3% (n = 29) in the
intermediate PvL group (median 63, range 51 to 98),
and 17.7% (n = 45) in the high PvL group (median 160
copies/1000 PBMCs, range 103 to 708). Extracted geno-
mic DNA from all subjects with intermediate PvL were
subjected to amplification and sequencing of the near
full-length HTLV-1 LTR. Due to financial constraints,
31 of the 182 genomic DNA samples from subjects with
low PvL and 34 of the 45 genomic DNA samples from
subjects with a high PvL were randomly selected and
their HTLV-1 LTR was successfully sequenced. The
demographic data from the three groups are listed in
Table 1. There were no differences in the age or sex
ratio between each group (p = 0.9 for age; p = 0.6 for
male to female ratio). A comparison of the stratified
PvLs showed no significant differences in any lympho-
cyte subpopulation percentages (p > 0.05). The trans-
continental subgroup A of HTLV-1a was the major
subtype; this accounted for 84% of low, 97% of inter-
mediate, and 96% of high PvL groups. There were no
differences in the subtype distribution between each
group (p = 0.2). Mutational analyses of the non-coding
regulatory sequences within the proviral LTR were con-
ducted to determine if a correlation exist between the
frequency of mutations and PvLs. These analyses
revealed two relevant G232A mutation within the
TRE-1 region and an A184G mutation within the TRE-2
region numbered according to the transcription start
site. The G232A mutation was detected in 38.7% (12/
31) of subjects with a low PvL, 27.5% (8/29) of subjects
with an intermediate PvL, and 61.8% (21/34) of subjects
with a high PvL (Table 1). A significant difference in
detection of the G232A mutation was found between
subjects with high and low PvLs and between those with
high and intermediate PvLs (p < 0.05 both). Non statisti-
cal difference was seen between the low and intermedi-
ate PvL groups (p > 0.05). Thirty-six of 41 (87.8%)
HTLV-1 G232A mutations were associated with a
simultaneous A to G mutation at position 184 (Figure
1). The distributions of this mutation according to PvL
groups was similar to the frequency of the G232A muta-
tion being found in 38.7% (12/31) in subjects with a low
PvL, 20.7% (6/29) in subjects with an intermediate PvL,
Table 1 Clinical and virological characteristics by proviral
load levels in subjects with available LTR sequences
Characteristics HTLV-1 proviral copies/1000 PBMCs
< 50 (n 31) 50-100 (n 29) > 100 (n 34)
Median age*. (range) 50 (26-71) 51 (24-70) 59.5 (21-95)
Sex
Male (%) 12 (39) 9 (31) 15 (44)
Female (%) 19 (61) 20 (69) 19 (56)
Lymphocyte subpopulations
% CD4 cells 42.9 45.2 46.8
% CD8 cells 28.2 27.3 29.1
% CD25 cells 20.3 22.6 29.8
Subtype A (%)
Subgroup A (%) 26 (84) 28 (97) 32 (96)
Subgroup B (%) 5 (16) 1(3) 2 (4)
Mutation
TRE-1 G232A (%) 12 (38.7) 8 (27.5) 21 (61.8)
TRE-1 A184G (%) 12 (38.7) 6 (20.7) 18 (52.9)
*Years
Neto et al. Virology Journal 2011, 8:535
http://www.virologyj.com/content/8/1/535
Page 3 of 7
and 52.9% (18/34) in subjects with a high PvL. Again, a
significant difference in detection of the A184G muta-
tion was evident between subjects with high and low
PvLs and betweeen those with high and intermediate
PvLs (p < 0.05 both), but not between the low and
intermediate PvL groups (p > 0.05). To confirm these
results, independent of the PvL grouping, a further sta-
tistical analysis using a Mann-Whitney test was per-
formed to compare the median PvL between subjects
infected with mutant viruses to those infected with
Enhancer I (TRE-1) Enahncer II (TRE-2) Enahncer III (TRE-3)
A B C A B C Ets-binding SP1-binding Ets-binding A B C Poly A signal TATA box















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
240 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
244 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
273 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
278 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
304 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
354 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
388 . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
398 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
493 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
693 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
471 . . . . . . . . . . . . . . . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
505 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
511 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
524 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
602 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
610 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
669 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
690 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
64 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
198 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
300 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
313 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
402 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
408 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
475 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
479 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
498 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
590 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
605 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
82 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
83 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
101 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
114 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
178 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
180 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
224 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
229 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
236 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
327 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
379 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
442 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
450 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
453 . . . . . . . . . . . . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
465 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
520 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
649 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
556 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
628 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
213 . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
243 . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
260 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
436 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
567 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
640 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
87 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
121 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
122 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
162 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
177 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
167 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
192 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
221 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
323 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
339 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
460 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
473 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . .
46 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
91 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
103 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
105 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
161 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
176 . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
179 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
241 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . .
247 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
298 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
415 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
429 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
439 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
457 . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
494 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
559 . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
578 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
619 . G . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1 Alignment of HTLV-1 LTR sequence elements determined from DNA amplified from 94 individuals with different
concentration of proviral loads: (31 low (< 50 copies/1000 PBMCs), 29 intermediate (50-100 copies/1000 PBMCs), and 34 high (> 100
copies/1000 PBMCs). Domains A, B and C are indicated by a gray background, and their position in the U3 region is presented relative to ATK
prototype (accession number J02029). Dots indicate nucleotide identity to the ATK prototype.
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wild-type viruses. This analysis revealed that while there
was strong evidence for a higher PvL among HTLV-1
positive individuals with the G232A mutation than
those without this mutation (42.2 vs. 54.4, p < 0.03),
there was no similar association among those who were
HTLV-1 positive with the A184G mutation (Figure 2).
Because these two analyses did not reach the same con-
clusion, we considered only G232A as a potential muta-
tion that could impact patient PvL. Other LTR motifs
associated with provirus transcriptional up-regulation
were inspected and were all found similar to a wild-type
genotype with few scattered natural point mutations
(Figure 1).
Discussion
In the present cross-sectional, retrospective study, we
investigated mutations in the LTR region of HTLV-1
and compared their association with asymptomatic car-
riers PvL. Our results showed that mutations were rela-
tively rare. However, a solitary, natural mutation at
position 232 was significantly associated with HTLV-1
infected subjects’ PvL. The G232A mutation is located
in domain A of the TRE-1 motif that contains non-con-
sensus CREB response elements and is involved in Tax-
activated and basal LTR expression. Although the func-
tional importance is unclear, it is possible that the
G232A mutation in the TRE1 element may enhance
indirect binding to Tax via the CREB family of cellular
transcription factors, thereby promoting the prolifera-
tion of infected cells and resulting in an increase in
patient PvLs. However, the validity of this hypothesis
needs to be investigated in an independent series of
experiments comparing the expression and activation of
the Tax gene in HTLV-1-infected T cells with or with-
out the G232A mutation. Previous reports have shown
that mutations that abolish Tax effects are all localized
in the CREB of the 21 bp repeats [38]. Montagne et al.
demonstrated that mutations introduced into domain A
or C can severely impair the ability of the Tax protein
to transactivate different promoters [31]. Taken
together, these data suggest that the TRE-1 element
plays an important role in the activation of HTLV-1
gene expression.
In our study, the G232A mutation was associated with
HTLV-1 PvL. Although the G232A mutation was
detected at a higher frequency in asymptomatic HTLV-1
carriers in this study, the frequency of such a mutation
is expected to be higher in patients with overt clinical
disease, because the PvLs of HTLV-1-infected patients
correlates with clinical outcome [35]. It is important to
note that our study is limited by the nature of its cross-
sectional design, and these results imply only a
Figure 2 Number of HTLV-1 subjects harboring wild-type or G232A and A184G mutant: viruses correlated with proviral loads. Black
lines represent the median proviral load for each group of subjects shown.
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correlation; therefore, no inferences can be made as to
the evolution of the wild-type viruses during chronic
infection. Therefore, longitudinal study designs are
required to address these issues and also to determine if
the G232A mutations was already present in patients
with advanced disease before they were diagnosed a
chronic infection.
Although the G232A mutation was detected in some
subjects with a low PvL in this study, further study is
needed to determine if this mutation is predictive of an
increase in PvL in patients who possess the mutation
but do not have an elevated PvL yet.
As shown in Figure 1, the G232A and A184G muta-
tions occurred together in almost all instances, most
likely because an HTLV strain with both mutations has
a higher selective advantage. Interestingly, none of the
subjects examined contain only the A184G mutations.
Therefore, additional experimental supports are needed
to rule out the potential importance of the A184G
mutations and functional connection between A184G
and G232A mutations.
Our analysis was limited to HTLV-1 subgroup A
because other subtypes are rare in our patients.
Whether similar results will be obtained for other sub-
groups, is of interest.
In conclusion, the results described here suggest the
G232A mutation in domain A of the TRE-1 motif may
increase HTLV-1 replication in the majority of infected
subjects.
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